Reducing levels of pro-inflammatory proteins such as CHGA and GFAP could be therapeutic for ALS and biomarkers such as APP, MAPT, and neurofilaments could confirm if filtration is modifying ALS progression meaningfully. Here, APP is linked to amyotrophic lateral sclerosis.